[3] Non-invasive approaches, such as 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography (CT) and the utilization of serum biomarkers [e.g.cancer antigen-125 (CA-125); human epididymis protein 4; Risk of Ovarian Malignancy Algorithm Index], notably CA-125, are gaining prominence for staging, assessing therapy response, and early recurrence detection. 4,
No takes yet. Share an insight, caveat, or question.
Ilieva-Gabarska et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: